FDA Brief

Warning letters Biologics

FDA warning letter to

Genovate

High riskIssued Jan 8Posted Jan 20Center for Biologics Evaluation and Research (CBER)

FDA warns Genovate over selling an unapproved HIV dried-blood-spot self-collection kit without marketing authorization.

What happened

FDA reviewed Genovate’s website, www.genovate.com, last visited in January 2026, and found the company offering an HIV dried blood spot card self-collection kit for delivery to individuals for self-collection and laboratory HIV testing. FDA said the kit has no approved premarket approval application (PMA) or investigational device exemption (IDE), and no required 510(k) notification was provided. FDA also said that after a March 31, 2025 letter, Genovate had not submitted any premarket submission for the kit.

What FDA found

  1. Genovate offered an HIV self-collection kit for sale in the United States without FDA marketing authorization.

    FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B)
  2. FDA says the kit is misbranded because Genovate did not notify FDA before introducing the device into commercial distribution as required by section 510(k).

    FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)
  3. The kit did not have an approved premarket approval application or an approved investigational device exemption.

    FD&C Act section 515(a), 21 U.S.C. 360e(a); section 520(g), 21 U.S.C. 360j(g)

What FDA wants

FDA asks Genovate to immediately stop any activities that make the HIV DBS card self-collection kit misbranded or adulterated and to notify FDA in writing within 15 working days of the steps taken to correct the violations and prevent recurrence.

Who should pay attention

  • makers of at-home diagnostic and self-collection kits
  • laboratories that receive self-collected samples
  • distributors and retailers selling HIV self-test kits

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk